Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2006-05-02
2006-05-02
Salimi, Ali R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S204100, C435S006120, C536S023720
Reexamination Certificate
active
07037509
ABSTRACT:
The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are epitopes confirmed to be recognized by T-cells derived from herpetic lesions. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.
REFERENCES:
patent: 4859587 (1989-08-01), Roizman
patent: 5632992 (1997-05-01), Nesburn et al.
patent: 5714152 (1998-02-01), Burke et al.
patent: 6017735 (2000-01-01), O'Hare et al.
patent: 6635258 (2003-10-01), Burke
patent: WO 92/02251 (1992-02-01), None
patent: WO 97/05265 (1997-02-01), None
patent: WO 98/04708 (1998-02-01), None
patent: WO 98/20016 (1998-05-01), None
patent: WO 00/08051 (2000-02-01), None
patent: WO 01/23414 (2001-05-01), None
E. De Plaen et al., “Cloning of Genes Coding for Antigens Recognized by Cytolytic T Lymphocytes,” Immunology Methods Manual, 1997, 692-718.
A. Dolan et al., “The Genome Sequence of Herpes Simplex Virus Type 2,” Journal of Virology, 1998, 72(3):2010-2021.
G. Elliott and P. O'Hare, “Intercellular Trafficking and Protein Delivery by a Herpesvirus Structural Protein,” Cell, 1997, 88:223-233.
D.M. Koelle et al., “Antigenic Specificities of Human CD+T-Cell Clones Recovered from Recurrent Genital Herpes Simples Virus Type 2 Lesions,” Journal of Virology, 1994, 68(5):2803-2810.
D.M. Koelle et al., “CD8 CTL from Genital Herpes Simplex Lesions Recognition of Viral Tegument and Immediate Early Proteins and Lysis of Infected Cutaneous Cells,” The Journal of Immunology, vol. 166(6): 4049-4058, Mar. 2001.
D.M. Koelle et al., “Clearance of HSV-2 from Recurrent Genital Lesions Correlates with Infiltration of HSV-Specific Cytotoxic T Lymphoctyes,” The Journal of Clinical Investigation, 1998, 101(7):1500-1508.
D.M. Koelle et al., “Direct Recovery of Herpes Simplex Virus (HSV)-Specific T Lymphocyte Clones from Recurrent Genital HSV-2 Lesions,” The Journal of Infectious Diseases, 1994, 169:956-61.
D.M. Koelle et al., “Preferrential Presentation of Herpes Simplex Virus T-Cell Antigen by HLA DQA1*0501/DQB1*0201 in Comparison to HLA DQA1*0201/DQB1*0201,” Human Immunology, 1997, 53(2):195-205.
D.M. Koelle et al., “Recognition of Herpes Simplex Virus Type 2 Tegument Proteins by CD4 T Cells . . . ” Journal of Virology, 1998, 72(9): 7476-7483.
D.M. Koelle, “The Roles of T Lymphocytes in Host Responses to Herpes Simplex Virus,” Herpes, 1995, 2:83-88.
W.W. Kwok et al., “Peptide Binding Affinity and pH Variation Establish Functional Thresholds for Activation of HLA-DQ-Restricted T Cell Recognition,” Human Immunology, 1999, 60(7);619-626.
Paoletti, “Applications of Pox Virus Vectors to Vaccination: An Update,” Proceedings of the National Academy of Science USA, Oct. 1996, 93:11349-11353.
C.M. Posavad et al., “High Frequency of CD8+Cytotoxic T-Lymphoctye Precursors Specific for Herpes Simplex Viruses in Persons with Genital Herpes,” Journal of Virology, 1996, 70(11):8165-8168.
S. Reichstetter et al., “MCH-Peptide Ligand Interactions Establish a Functional Threshold for Antigen-Specific T Cell Recognition,” Human Immunology, 1999, 60(7):608-618.
B. Roizman et al., “Herpes Simplex Viruses and Their Replication”, Fundamental Virology, 2ndEdition, ed. Fields et al, Raven Press, 1991, New York, pp. 849-895.
Tatman, J.D. et al., “Assembly of Herpes Simplex Virus Type 1 Using a Panel of Recombinant Baculoviruses,” Journal of General Virology, 1994, 75, 1101-1113.
M.A. Tigges et al., “Human CD8* Herpes Simplex Virus-Specific Cytotoxic T-Lymphocyte Clones Recognize Diverse Virion Protein Antigens,” Journal of Virology, 1992, 66(3):1622-1634.
Williams et al., “Characterization of a Herpes Simplex Virus Type 2 Deoxyuridine . . . ” Virology, 1987, 156:282-292.
Chen Hongbo
Hosken Nancy A.
Koelle David M.
McGowan Patrick
Posavad Christine M.
Corixa Corporation
Fred Hutchinson Cancer Research Center
Gates & Cooper LLP
Salimi Ali R.
University of Washington
LandOfFree
Immunologically significant herpes simplex virus antigens... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunologically significant herpes simplex virus antigens..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunologically significant herpes simplex virus antigens... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3646484